Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Sanson

Showing results (271-280 of 290) with videos related to

Pageof 29
Sort By:
Cancer Cell|January 12, 2024
Integrated proteogenomic characterization of glioblastoma evolutionKyung-Hee Kim, Simona Migliozzi, Harim Koo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Human Molecular Genetics|May 3, 2011
Chromosome 7p11.2 (EGFR) variation influences glioma riskMarc Sanson, Fay J Hosking, Sanjay Shete, et al.
Trends in Cancer|November 18, 2022
Challenges in glioblastoma research: focus on the tumor microenvironmentAndreas Bikfalvi, Cristine Alves da Costa, Tony Avril, et al.
Nature Medicine|December 12, 2018
The molecular landscape of glioma in patients with Neurofibromatosis 1Fulvio D'Angelo, Michele Ceccarelli, Tala, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Neuro-Oncology|April 25, 2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directionsPatrick Y Wen, Michael Weller, Eudocia Quant Lee, et al.
Pageof 29

Showing results (271-280 of 290) with videos related to

Sort By:
Pageof 29
Cancer Cell|January 12, 2024
Integrated proteogenomic characterization of glioblastoma evolutionKyung-Hee Kim, Simona Migliozzi, Harim Koo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Human Molecular Genetics|May 3, 2011
Chromosome 7p11.2 (EGFR) variation influences glioma riskMarc Sanson, Fay J Hosking, Sanjay Shete, et al.
Trends in Cancer|November 18, 2022
Challenges in glioblastoma research: focus on the tumor microenvironmentAndreas Bikfalvi, Cristine Alves da Costa, Tony Avril, et al.
Nature Medicine|December 12, 2018
The molecular landscape of glioma in patients with Neurofibromatosis 1Fulvio D'Angelo, Michele Ceccarelli, Tala, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Neuro-Oncology|April 25, 2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directionsPatrick Y Wen, Michael Weller, Eudocia Quant Lee, et al.
Pageof 29